1TM Stock Overview
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Mithra Pharmaceuticals SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.18 |
52 Week High | €3.15 |
52 Week Low | €0.16 |
Beta | 0.45 |
1 Month Change | -30.38% |
3 Month Change | -83.90% |
1 Year Change | -93.63% |
3 Year Change | -99.25% |
5 Year Change | -99.29% |
Change since IPO | -98.45% |
Recent News & Updates
Recent updates
Shareholder Returns
1TM | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0.6% | 2.3% | 0.5% |
1Y | -93.6% | -28.6% | 1.3% |
Return vs Industry: 1TM underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 1TM underperformed the German Market which returned 2.3% over the past year.
Price Volatility
1TM volatility | |
---|---|
1TM Average Weekly Movement | 26.3% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1TM's share price has been volatile over the past 3 months.
Volatility Over Time: 1TM's weekly volatility has increased from 18% to 26% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 270 | Christophe Marechal | www.mithra.com |
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications.
Mithra Pharmaceuticals SA Fundamentals Summary
1TM fundamental statistics | |
---|---|
Market cap | €15.20m |
Earnings (TTM) | -€173.50m |
Revenue (TTM) | €40.16m |
0.4x
P/S Ratio-0.1x
P/E RatioIs 1TM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1TM income statement (TTM) | |
---|---|
Revenue | €40.16m |
Cost of Revenue | €21.95m |
Gross Profit | €18.21m |
Other Expenses | €191.71m |
Earnings | -€173.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | -2.51 |
Gross Margin | 45.34% |
Net Profit Margin | -432.08% |
Debt/Equity Ratio | -258.9% |
How did 1TM perform over the long term?
See historical performance and comparison